An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
New Labcorp Test Report Helps Identify Insect Stings and Improve Therapy Decisions to Combat Allergic Reactions
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Labcorp has launched a unique Clinical Decision Support (CDS) interpretative report for its Stinging Insect Component-Specific IgE Test. This test aims to enhance patient management regarding venom allergies, impacting nearly 10 million Americans. The report, developed with input from leading experts, offers specific allergen identification and treatment suggestions, aiming to improve the efficacy of venom immunotherapy. Labcorp remains the only reference laboratory offering such testing, supporting healthcare providers in diagnosing and managing insect venom allergies effectively.
Positive
Launch of the unique Labcorp CDS interpretative report for Stinging Insect Component-Specific IgE Test.
Addresses a significant market, impacting nearly 10 million people in the U.S.
Developed in collaboration with leading experts, enhancing credibility and trust.
BURLINGTON, N.C.--(BUSINESS WIRE)--
Nearly 10 million people in the United States have a history of systemic or anaphylactic reaction to insect stings, with the risk of a severe and potentially life-threatening allergic reaction. To help facilitate more effective venom therapy, Labcorp (NYSE: LH), a leading global life sciences company, has launched its unique Labcorp Clinical Decision Support (CDS) interpretative test report for its Stinging Insect Component-Specific IgE Test that provides allergen test interpretation and treatment suggestions.
Photo courtesy of Labcorp
“Labcorp is the only reference laboratory to offer stinging insect (venom) component testing,” said Dr. Andre Valcour, vice president and laboratory director of Labcorp Diagnostic’s esoteric testing unit. “The launch of this new interpretative report is another example of how Labcorp continues to provide clinical expertise and value to providers and patients by identifying specific insect species for therapy and offering guidance on successful venom immunotherapy.”
Over half of stinging insect patients test positive for allergic reactions to both honeybee and yellow jacket (wasp) venom. Labcorp’s Stinging Insect Component-Specific IgE Testing helps identify the specific venom to which the patient is allergic and provides a more precise diagnosis to support venom immunotherapy. Venom-specific immunotherapy (VIT) is an effective treatment for venom allergy that can help protect against future reactions, minimize side effects and lower treatment costs.
The Labcorp CDS interpretative venom allergy report expands on prior reporting to provide report interpretation and uses current Allergy Practice Parameters, which are sponsored by the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology, to offer treatment suggestions. Dr. David Golden, a leading expert on stinging insect allergies and former chair of the Stinging Insect Hypersensitivity Practice Parameter Update workgroup, collaborated with Labcorp to establish this vital report.
“It is very important to identify the specific insect species for effective therapy,” said Dr. Golden, an associate professor of medicine at Johns Hopkins University and the allergy division chief at both Sinai Hospital and Franklin Square Hospital in Baltimore, Maryland. “Venom component testing is valuable as it can differentiate between species-specific sensitization and cross-reactivity, fine tune venom diagnosis, and help physicians determine the most appropriate and cost-effective treatment plans for patients.”
The Labcorp CDS interpretive report follows the Practice Parameters and provides physicians comprehensive insight on diagnostic marker interpretation, treatment suggestions and guidance for managing venom and stinging insect therapy. To learn about the Practice Parameters, visit their website.
About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
